TScan Therapeutics to Participate in Upcoming Investor Conferences
TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical firm, announced participation in two investor conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical firm, announced participation in two investor conferences. The Jefferies Cell and Genetic Medicine Summit will take place in New York on September 29, 2022, at 1:30 p.m. ET, followed by Chardan’s 6th Annual Genetic Medicines Conference on October 3, 2022, at 4:00 p.m. ET. Both events will feature fireside chats. Webcasts will be available on the company's website, with archived replays accessible for 30 days post-event.
Details
News Market Reaction – TCRX
The recorded move for TCRX in the trading session of this news was -8.28%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., Sept. 22, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that management will participate in the following upcoming investor conferences:
- Jefferies Cell and Genetic Medicine Summit; the fireside chat will be held at the Lotte New York Palace in New York, NY on Thursday, September 29, 2022 at 1:30 p.m. ET
- Chardan’s 6th Annual Genetic Medicines Conference; the fireside chat will be held at the Westin Grand Central in New York, NY on Monday, October 3, 2022 at 4:00 p.m. ET
Webcasts of each fireside chat will be available on the “Events and Presentations” section of the Company’s website at www.ir.tscan.com. An archived replay of the webcast will be available on the Company’s website for 30 days following the event.
About TScan Therapeutics, Inc.
TScan is a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after hematopoietic stem cell transplantation. The Company is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors. The Company has developed and continues to build its ImmunoBank, the Company’s repository of therapeutic TCRs that recognize diverse targets and are associated with multiple HLA types in order to provide customized multiplexed TCR-T therapies for patients with a variety of solid tumors.
Contacts
Heather Savelle
TScan Therapeutics, Inc.
VP, Investor Relations
857-399-9840
hsavelle@tscan.com
Joyce Allaire
LifeSci Advisors, LLC
Managing Director
617-435-6602
jallaire@lifesciadvisors.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.